Drugs / Dilpacimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01946074 | Aug 2013 → Sep 2022 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03368859 | Mar 2018 → Dec 2019 | cancer | AbbVie | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dilpacimab | “Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.” PMID 34315767 ↗ Jul 20211“Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in” PMID 35920133 ↗ Aug 2022 |
| Known as | ABT-165 | “Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.” PMID 34315767 ↗ Jul 20211“Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in” PMID 35920133 ↗ Aug 2022 |
| Known as | PR-1283233 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594306 ↗ |
| Modality | Monoclonal antibody | “Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.” PMID 34315767 ↗ Jul 2021 |
| Route | Intravenous | “Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25-7.5 mg/kg) until progressive disease or...” PMID 34315767 ↗ Jul 2021 |
| Target | DLL4 | “Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.” PMID 34315767 ↗ Jul 2021 |